Gerstein, Hertzel C.

Poor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes

Punthakee, Z., Miller, M. E., Launer, L. J., Williamson, J. D., Lazar, R. M., Cukierman-Yaffee, T., Seaquist, E. R., Ismail-Beigi, F., Sullivan, M. D., Lovato, L. C., et al. (2012) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 337

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial

Holman, R. R., Coleman, R. L., Chan, J. C. N., Chiasson, J.-L., Feng, H., Ge, J., Gerstein, H. C., Gray, R., Huo, Y., Lang, Z., et al. (2017) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 323

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events

Gangji, A. S., Cukierman, T., Gerstein, H. C., Goldsmith, C. H., & Clase, C. M. (2007) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 308

Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss

Day, E. A., Ford, R. J., Smith, B. K., Mohammadi-Shemirani, P., Morrow, M. R., Gutgesell, R. M., Lu, R., Raphenya, A. R., Kabiri, M., McArthur, A. G., et al. (2019) · Nature Metabolism

GDF15 and Related BiomarkersRegulation of Appetite and Obesity

Cited by 307

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

Cukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L.-E., Lakshmanan, M., Bethel, A., Xavier, D., Probstfield, J., Riddle, M. C., et al. (2020) · The Lancet Neurology

Diabetes Treatment and ManagementDementia and Cognitive Impairment Research

Cited by 300

The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis

Gerstein, H. C., Pogue, J., Mann, J. F. E., Lonn, E., Dagenais, G. R., McQueen, M., Yusuf, S., & HOPE investigators (2005) · Diabetologia

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 262

Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial

Margolis, K. L., O’Connor, P. J., Morgan, T. M., Buse, J. B., Cohen, R. M., Cushman, W. C., Cutler, J. A., Evans, G. W., Gerstein, H. C., Grimm, R. H., et al. (2014) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 259

The DREAM trial – Authors' reply

Gerstein, H. C., Yusuf, S., & Bosch, J. (2006) · The Lancet

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 253

Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial

The ORIGIN Trial Investigators, Mellbin, L. G., Rydén, L., Riddle, M. C., Probstfield, J., Rosenstock, J., Díaz, R., Yusuf, S., & Gerstein, H. C. (2013) · European Heart Journal

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 247

Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): A double-blind randomised controlled study

Zinman, B., Harris, S. B., Neuman, J., Gerstein, H. C., Retnakaran, R. R., Raboud, J., Qi, Y., & Hanley, A. J. (2010) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 235

Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

Goff, D. C., Gerstein, H. C., Ginsberg, H. N., Cushman, W. C., Margolis, K. L., Byington, R. P., Buse, J. B., Genuth, S., Probstfield, J. L., & Simons-Morton, D. G. (2007) · The American Journal of Cardiology

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 229

The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure: An Analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program

Gerstein, H. C. (2008) · Archives of Internal Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 217

A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose‐lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study

Gerstein, H. C., Yale, J. ‐., Harris, S. B., Issa, M., Stewart, J. A., & Dempsey, E. (2006) · Diabetic Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 197

Cognitive Function and Brain Structure in Persons With Type 2 Diabetes Mellitus After Intensive Lowering of Blood Pressure and Lipid Levels: A Randomized Clinical Trial

Williamson, J. D., Launer, L. J., Bryan, R. N., Coker, L. H., Lazar, R. M., Gerstein, H. C., Murray, A. M., Sullivan, M. D., Horowitz, K. R., Ding, J., et al. (2014) · JAMA Internal Medicine

Dementia and Cognitive Impairment ResearchDiabetes Treatment and Management

Cited by 187

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes

Elam, M. B., Ginsberg, H. N., Lovato, L. C., Corson, M., Largay, J., Leiter, L. A., Lopez, C., O’Connor, P. J., Sweeney, M. E., Weiss, D., et al. (2017) · JAMA Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 185

Does a Combination Regimen of Thyroxine (T4) and 3,5,3′-Triiodothyronine Improve Depressive Symptoms Better Than T4Alone in Patients with Hypothyroidism? Results of a Double-Blind, Randomized, Controlled Trial

Sawka, A. M., Gerstein, H. C., Marriott, M. J., MacQueen, G. M., & Joffe, R. T. (2003) · The Journal of Clinical Endocrinology & Metabolism

Thyroid Disorders and TreatmentsThyroid and Parathyroid Surgery

Cited by 175

Adipocyte hypertrophy, fatty liver, and metabolic risk factors in South Asians: The Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE)

Anand, S. S., Tarnopolsky, M. A., Rashid, S., Schulze, K. M., Desai, D., Mente, A., Rao, S., Yusuf, S., Gerstein, H. C., & Sharma, A. M. (2011) · PLoS ONE

Adipokines, Inflammation, and Metabolic DiseasesCardiovascular Disease and Adiposity

Cited by 174

Growth Differentiation Factor 15 as a Novel Biomarker for Metformin

Gerstein, H. C., Pare, G., Hess, S., Ford, R. J., Sjaarda, J., Raman, K., McQueen, M., Lee, S., Haenel, H., & Steinberg, G. R. (2017) · Diabetes Care

GDF15 and Related BiomarkersDiabetes Treatment and Management

Cited by 169

Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis

Neuen, B. L., Fletcher, R. A., Heath, L., Perkovic, A., Vaduganathan, M., Badve, S. V., Tuttle, K. R., Pratley, R., Gerstein, H. C., Perkovic, V., et al. (2024) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 168

Adolescent Obesity and Early-Onset Type 2 Diabetes

Twig, G., Zucker, I., Afek, A., Cukierman-Yaffe, T., Bendor, C. D., Derazne, E., Lutski, M., Shohat, T., Mosenzon, O., Tzur, D., et al. (2020) · Diabetes Care

Obesity, Physical Activity, DietDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 161

HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression

Bethel, M. A., Diaz, R., Castellana, N., Bhattacharya, I., Gerstein, H. C., & Lakshmanan, M. C. (2021) · Diabetes Care

Diabetes Treatment and ManagementRetinal Diseases and Treatments

Cited by 151

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial

Gerstein, H. C., Hart, R., Colhoun, H. M., Diaz, R., Lakshmanan, M., Botros, F. T., Probstfield, J., Riddle, M. C., Rydén, L., Atisso, C. M., et al. (2020) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementAcute Ischemic Stroke Management

Cited by 137

Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial

Lam, C. S. P., Ramasundarahettige, C., Branch, K. R. H., Sattar, N., Rosenstock, J., Pratley, R., Del Prato, S., Lopes, R. D., Niemoeller, E., Khurmi, N. S., et al. (2022) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 132

The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression

Samaan, Z., Anand, S., Zhang, X., Desai, D., Rivera, M., Pare, G., Thabane, L., Xie, C., Gerstein, H., Engert, J. C., et al. (2013) · Molecular Psychiatry

Genetic Associations and EpidemiologyNeurotransmitter Receptor Influence on Behavior

Cited by 129